Breast cancer

07 June 2012

Blood test can save breast cancer patients

A blood test can save lives by helping docs swiftly diagnose whether a patient with early breast cancer faces high risk of death or relapse after treatment, specialists said.


A simple blood test can save lives by helping doctors swiftly diagnose whether a patient with early breast cancer faces high risk of death or relapse after treatment, specialists said.

Tumour cells in a blood sample, when taken at an early stage of the disease, are an accurate predictor of a patient's survival chances, the team said in the journal The Lancet Oncology.

The findings could help identify early on which patients might benefit from additional treatment like chemotherapy.

"The presence of one or more circulating tumour cells (CTCs, in the blood) predicted early recurrence and decreased overall survival," said the researchers from the University of Texas' MD Anderson Cancer Centre. The more CTCs they found, the higher the risk of death.

Tumours spread through lymphatic system

CTC blood tests are not currently used to analyse a patient's prognosis or prescribe treatment, as cancer tumours are generally thought to spread through the lymphatic system rather than the bloodstream.

The team conducted tests on 302 patients treated at the centre between February 2005 and December 2010.

The subjects were at an early phase of breast cancer – before it spread to other parts of the body – and had not received chemotherapy.

The team found CTCs in a quarter of the group.

Of those with tumour cells in their blood, one in seven relapsed after treatment and one in 10 died during the test period.

Large clinical studies needed

By contrast, patients whose blood tests yielded no CTCs had a relapse rate of 3% and a death rate of 2%.

"For patients with a higher concentration of CTCs, the correlation with survival and progression rates was even more dramatic, with 31% of these patients dying or relapsing," said a press release accompanying the study.

Previous research showed similar results in patients with breast cancer that had already metastasised, or spread. The new study claims to show that "advanced disease is not necessary for cancer cells to spread (via the blood) and compromise survival."

Others urged caution, saying the research was in its infancy and urging larger clinical studies.

No clarity on what to do

"It's great work and very well conducted. We just don't know how to act on the study yet, ie what to do differently with our patients," Justin Stebbing of the Department of Surgery and Cancer at London's Imperial College told AFP.

In particular, it was not clear whether the CTC count must be measured before, during or after surgery to remove the cancerous growth.

Nor was it clear what effect chemotherapy would have on the CTC markers.

(Sapa, June 2012) 

Read more:

Breast cancer

Some breast cancer tumours resistant to chemotherapy


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules